NCT01986712View on ClinicalTrials.gov

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 18, 2018

Study Completion Date

September 17, 2019

Conditions

Melanoma

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

18015

St Luke's University Hospital and Health Network, Bethlehem

33612

Moffit Cancer Center, Tampa

84112-5550

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

St. Luke's Hospital and Health Network, Pennsylvania

OTHER

NCT01986712 - A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma | Biotech Hunter | Biotech Hunter